SLU-PP-332: A Pan-ERR Agonist Studied in Metabolic Research

SLU-PP-332 is generating significant excitement in metabolic research. This synthetic agonist activates the same cellular pathways triggered by aerobic exercise.

What Is SLU-PP-332?

SLU-PP-332 is a synthetic small molecule compound developed through nearly a decade of research at Washington University and St. Louis University. It functions as a pan-agonist for estrogen-related receptors (ERRs) – a family of nuclear receptors that regulate energy metabolism, mitochondrial function, and exercise adaptation.

Unlike estrogen receptors, ERRs function as “orphan” nuclear receptors with no known natural ligand. When activated, they turn on hundreds of genes associated with aerobic exercise, mitochondrial biogenesis, and fatty acid oxidation.

SLU-PP-332 activates all three ERR subtypes:

• ERRα – Regulates exercise-induced stress adaptation (highest potency)
• ERRβ – Involved in metabolic regulation
• ERRγ – Critical for cardiac function and energy metabolism

How SLU-PP-332 Works

When you exercise, oxygen demand in muscle cells increases, triggering ERR expression. This leads to cellular adaptations that improve fuel utilization and endurance.

SLU-PP-332 mimics this exact process pharmacologically:

1. Binds to ERR receptors on muscle, heart, and metabolic tissues
2. Activates transcription of exercise-related genes
3. Increases mitochondrial biogenesis (more cellular powerhouses)
4. Shifts muscle fiber type toward oxidative, fatigue-resistant Type IIa fibers
5. Enhances fatty acid oxidation as primary fuel source
6. Increases energy expenditure even at rest

Key genes activated include:

• PGC-1α – Master regulator of mitochondrial biogenesis
• GLUT4 – Glucose transporter upregulated by exercise
• Oxidative phosphorylation components
• Fatty acid metabolism enzymes

What the SLU-PP-332 Research Shows

Enhanced Exercise Endurance

The landmark 2023 study in ACS Chemical Biology demonstrated:

• Increased Type IIa oxidative muscle fibers (fatigue-resistant)
• Enhanced exercise endurance on treadmill protocols
• Improved mitochondrial function and cellular respiration
• Induced an ERRα-specific acute aerobic exercise genetic program

Importantly, ERRα knockout mice showed no endurance benefit – confirming the mechanism depends on ERR activation.

Metabolic Syndrome & Obesity

A 2024 study in Journal of Pharmacology and Experimental Therapeutics examined SLU-PP-332 in obese mice:

Diet-Induced Obese Mice (28 days):

• Increased resting energy expenditure
• Increased fatty acid oxidation
• Decreased fat mass accumulation
• Improved blood lipid profiles
• No change in food intake

ob/ob Mice (genetic obesity model, 12-15 days):

• Reduced body weight and fat mass
• Reduced liver weight
• Improved liver histology (reduced fat accumulation)
• Increased fatty acid oxidation during both day and night

Improved Insulin Sensitivity

Treatment improved glucose tolerance and insulin sensitivity:

• Lower fasting blood glucose
• Improved glucose tolerance tests
• Improved pyruvate tolerance tests
• Increased muscle glucose uptake

Heart Failure Protection

Studies in pressure overload-induced heart failure models showed:

• Significantly improved ejection fraction
• Reduced cardiac fibrosis
• Increased survival
• Improved mitochondrial ultrastructure
• Reduced expression of heart failure markers (Nppa/Nppb)
• Enhanced fatty acid metabolism in cardiac tissue

The research found that ERRγ is the main mediator of cardioprotection, while the metabolic benefits depend more on ERRα.

Muscle Atrophy Prevention

A 2025 pilot study examined SLU-PP-332 in human myoblasts from inactive elderly individuals:

Treatment effects:

• Reduced oxidative stress (lower ROS, higher glutathione)
• Reduced cellular senescence (lower SA-β-galactosidase)
• Increased FNDC5 expression (irisin precursor)
• Upregulated SIRT1 and PGC-1α
• Enhanced myotube formation and differentiation
• Activated anti-apoptotic pathways (Akt, Bcl-2)

This suggests potential applications for sarcopenia and age-related muscle loss.

SLU-PP-332 vs. Other Exercise Mimetics

Compound	Target	Primary Effect
SLU-PP-332	ERRα/β/γ	Acute aerobic exercise program, endurance
GW501516 (Cardarine)	PPARδ	Fatty acid oxidation, endurance
SR9009 (Stenabolic)	REV-ERB	Circadian rhythm, metabolism
AICAR	AMPK	Energy sensing, glucose uptake

SLU-PP-332 is unique in inducing an acute aerobic exercise genetic program – this was not reported for PPARδ or REV-ERB agonists.

Important Considerations

• SLU-PP-332 is still in preclinical development
• No human clinical trials have been completed
• Currently available for research purposes only
• A startup company (Pelagos Pharmaceuticals) has been founded to advance development
• Newer compounds are being developed with improved potency and brain penetration

The Bottom Line

SLU-PP-332 represents a genuine breakthrough in exercise mimetic research. By activating the ERR pathway, it triggers the same cellular adaptations as aerobic exercise. While it can’t replace exercise entirely (“exercise is important on all levels,” as the researchers note), it offers remarkable potential for treating metabolic disease, heart failure, and age-related muscle decline.

---

Disclaimer: This article is for educational purposes only. NexGen Peptides products are intended for laboratory research use only. Not for human consumption. SLU-PP-332 has not been approved by the FDA for any medical use.

References:

1. Billon C, et al. Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response. ACS Chem Biol. 2023.
2. Billon C, et al. A Synthetic ERR Agonist Alleviates Metabolic Syndrome. J Pharmacol Exp Ther. 2024.
3. Xu W, et al. Novel Pan-ERR Agonists Ameliorate Heart Failure. Circulation. 2024.